Merck
Private Company
Funding information not available
Overview
Merck & Co. is a research-intensive biopharmaceutical giant with a foundational mission to put medicine before profits, driving global health impact. Its strategic focus is on high-growth therapeutic areas, most notably oncology led by blockbuster KEYTRUDA, complemented by a robust vaccine portfolio and promising pipeline. The company leverages a multi-modal technology platform and significant financial strength to sustain innovation, navigate patent cliffs, and pursue strategic business development to fuel long-term growth.
Technology Platform
A multi-modal platform integrating AI/ML (KERMT model), deep immuno-oncology expertise, advanced biologics engineering, vaccine technology, and precision medicine capabilities to accelerate drug discovery and development across small molecules, antibodies, and novel modalities.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| PEG-IFN alfa-2b + RBV | Chronic Hepatitis C | Pre-clinical | |
| Raltegravir (Isentress®) | HIV | Pre-clinical | |
| ARQ 092 | Proteus Syndrome | Pre-clinical | |
| Cetuximab | Neoplasms, Squamous Cell | Pre-clinical | |
| Januvia (Sitagliptin) 100 mg + Placebo | Type 2 Diabetes | Pre-clinical |
FDA Approved Drugs
43Opportunities
Risk Factors
Competitive Landscape
Merck faces intense competition across all segments: in oncology from Bristol Myers Squibb, Roche, and AstraZeneca; in vaccines from GSK, Pfizer, and Sanofi; and in emerging areas from both large pharma and agile biotechs. Its competitive advantages are scale, commercial execution, the KEYTRUDA franchise, and a strong balance sheet for business development.
Company Timeline
Founded in Rahway, United States
FDA Approval: WINREVAIR
FDA Approval: KEYTRUDA QLEX
FDA Approval: ENFLONSIA